Pharmaceutical firm Cronus Pharma attracts private equity investment four years following the collapse of a business agreement with Aurobindo
In the realm of business developments, a significant shift has occurred in the animal healthcare sector. Cronus Pharma, a company renowned for manufacturing general and cephalosporin veterinary finished dosage formulations, has caught the attention of several private equity investors. According to sources familiar with the matter, these investors have shown interest in Cronus Pharma as of August 2025 [1].
However, the identities of these private equity firms remain undisclosed. The interest in Cronus Pharma follows a previous failed acquisition attempt by Aurobindo Pharma in 2021 [1].
Meanwhile, other entities making headlines include Axis Finance and Maple Infra, which have attracted potential investors. The specific nature or reasons behind this interest remain unclear.
In a separate development, PE/VC firms have managed to rake in $3 billion through exits within a month, utilising the stock market rally. Entities such as Advent, TPG, Kedaara, ChrysCap, Goldman Sachs, Temasek, and Xponentia have been mentioned in recent news.
Another company under the spotlight is OmniActive, where PE firms and strategics are reportedly considering an investment. Concurrently, TA Associates is planning an exit from OmniActive.
Lastly, Apollo Hospitals, a leading name in healthcare, has announced plans to list its digital health and pharmacy unit within 18-21 months. The details about the digital health and pharmacy unit have not been disclosed.
In a related note, LendingKart's Lunia has stepped down from his position, but the context of this move in relation to the aforementioned entities remains unclear.
[1] Source: Unnamed sources familiar with the development.
Finance-related entities Axis Finance and Maple Infra have attracted potential investors, but the specific nature or reasons behind this interest remain unclear.
PE/VC firms, including Advent, TPG, Kedaara, ChrysCap, Goldman Sachs, Temasek, and Xponentia, have managed to rake in $3 billion through exits within a month, utilising the stock market rally, suggesting a burgeoning interest in finance-based activities.
